Pharmacotherapy for obesity

British Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2009, Pages 804-810

  Li, Mingfang ^a   Cheung, Bernard M Y ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anti obesity drugs; Orlistat; Rimonabant; Sibutramine

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; BUPROPION PLUS NALTREXONE; CAFFEINE; CETILISTAT; CONTRAVE; CP 945598; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; GLUCAGON LIKE PEPTIDE 1; GT 389 255; HUMAN GROWTH HORMONE[176-191][176 TYROSINE]; LEPTIN; LORCASERIN; PEPTIDE YY [3-36]; PHENTERMINE; PHENTERMINE PLUS TOPIRAMINE; PHENYLPROPANOLAMINE; PLACEBO; PRAMLINTIDE; QNEXA; RIMONABANT; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN; TM 30338; TRANDOLAPRIL; UNCLASSIFIED DRUG; VERAPAMIL;

ABDOMINAL PAIN; AGITATION; ANXIETY; BEHAVIOR THERAPY; BLOATING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ENERGY EXPENDITURE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPID ABSORPTION; NERVOUSNESS; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; STROKE; THERMOGENESIS; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTONES; LIPASE; META-ANALYSIS AS TOPIC; OBESITY; PIPERIDINES; PYRAZOLES; TIME FACTORS;

EID: 70849093104     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03453.x     Document Type: Review

References (55)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003 289 : 76 9.
2. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004 11 : 3 8.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 295 : 1549 55.
4. Hubert H, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983 67 : 968 77.
5. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998 351 : 853 6.
6. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001 345 : 790 7. (Pubitemid 34940842)
7. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003 11 : 1223 31.
8. World Health Organization. Obesity: Preventing and managing the global epidemic Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997). Geneva : WHO, 1998.
9. Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obes Res 1995 3 : 73 95.
10. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005 142 : 525 31.
11. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD, Bravata DM. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003 289 : 1837 50.
12. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003 348 : 2074 81. (Pubitemid 36583302)
13. Yancy WS Jr., Olsen MK, Guyton JR, Bakst RP, Westman EC. A low carbohydrate,ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004 140 : 769 77.
14. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 353 : 2111 20.
15. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992 16 : 397 415.
16. Van Gaal LF, Wauters MA, de Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997 21 : s5 9.
17. Leung WYS, Thomas GN, Chan JCN, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clinical Therapeutics 2003 25 : 58 80.
18. Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol 2005 2 : 89 95.
19. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006 29 : 277 302.
20. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993 119 : 707 13.
21. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002 26 : 262 73.
22. Valle-Jones JC, Brodie NH, O'Hara H, O'Hara J, McGhie RL. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. Pharmatherapeutica 1983 3 : 300 4.
23. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 337 : 581 8.
24. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis pharmacologic treatment of obesity. Ann Intern Med 2005 142 : 532 46.
25. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000 1 : 127 39.
26. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004 164 : 994 1003.
27. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998 56 : 1093 124. (Pubitemid 29010230)
28. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 2005 29 : 509 16.
29. Nakou E, Filippatos TD, Liberopoulos EN, Tselepis AD, Kiortsis DN, Mikhailidis DP, Elisaf MS. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008 9 : 1629 39.
30. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Krüger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006 79 : 500 8.
31. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 28 : 2915 23.
32. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005 365 : 1363 4.
33. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorization of Acomplia press release] Oct 23, 2008. Available at: http://www.emea.europa.eu (Doc. Ref.: EMEA/CHMP/537777/2008) .
34. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004 3 : 771 84.
35. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rösser S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 97. (Pubitemid 40523733)
36. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006 295 : 761 75.
37. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 34.
38. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 : 1660 72.
39. Samat A, Tomlinson B, Taheri S, Thomas GN. Rimonabant for the treatment of obesity. Recent Pat Cardiovas Drug Discov 2008 3 : 187 93.
40. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997 21 : s12 23.
41. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 56 : 82 5.
42. US Food and Drug Administration. FDA approves orlistat for obesity. [press announcement] Febuary 7, 2007. Available at http://www.fda.gov/bbs/ topics/NEWS/2007/NEW01557.html.
43. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 61. (Pubitemid 38196725)
44. Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005 330 : 157 60.
45. Beck-da-Silva L, Higginson L, Frasser M, Williams K, Haddad H. Effect of orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005 11 : 118 23.
46. Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabetic Med 2005 22 : 1737 43.
47. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 293 : 2873 83.
48. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006 12 : 18 28.
49. Hirsch B. Review of anti-obesity medications currently under development. Am J Bar Med 2000 15 : 16 23.
50. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006 5 : 919 31.
51. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr., Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007 321 : 1013 22.
52. Melnikova I, Wages D. Anti-obesity therapies. Nat Rev Drug Discov 2006 5 : 369 70.
53. Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 2007 154 : 19 28.
54. Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity: new perspectives and pharmacotherapies. Cardiol Rev 2006 14 : 238 58.
55. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B LEAD-3 (Mono) Study Group. Liraglutide vs glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009 373 : 473 81.